Adaptive Biotechnologies
ADPT
Market cap $1.8B

11.82 USD

-0.26

2.15%

At close Jul 11, 4:00 PM EDT

After hours

11.82

+0.00

0.00%

1 day

-2.15%

5 days

-0.17%

1 month

11.19%

3 months

48.87%

6 months

82.97%

Year to date

90.95%

1 year

203.86%

5 years

-73.25%

10 years

-70.67%

About: Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Employees: 619

Healthcare Biotechnology

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

116% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 19

32% more capital invested

Capital invested by funds: $859M [Q4 2024] → $1.14B (+$278M) [Q1 2025]

9% more funds holding

Funds holding: 207 [Q4 2024] → 226 (+19) [Q1 2025]

5.84% more ownership

Funds ownership: 97.09% [Q4 2024] → 102.93% (+5.84%) [Q1 2025]

9% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 67

3% more call options, than puts

Call options by funds: $383K | Put options by funds: $372K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$9

24%

downside

Avg. target

$11.75

1%

downside

High target

$15

27%

upside

4 analyst ratings

3 positive

75%

1 neutral

25%

0 negative

0%

Craig-Hallum John Wilkin	27%upside $15	Buy Initiated	18 Jun 2025
Piper Sandler David Westenberg	10%upside $13	Overweight Maintained	6 May 2025
Morgan Stanley Tejas Savant	24%downside $9	Equal-Weight Maintained	5 May 2025
Goldman Sachs Salveen Richter	15%downside $10	Buy Maintained	2 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about ADPT published over the past 30 days

Zacks Investment Research

Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?

Here is how Adaptive Biotechnologies (ADPT) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?

Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

clonoSEQ® is now integrated into Flatiron Health's OncoEMR®, simplifying MRD testing access for over 4,500 clinicians across the Flatiron network.

Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

Zacks Investment Research

Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains?

Adaptive Biotechnologies (ADPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains?

Zacks Investment Research

What Makes Adaptive Biotechnologies (ADPT) a New Buy Stock

Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Adaptive Biotechnologies (ADPT) a New Buy Stock

Zacks Investment Research

Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.

Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in 30 presentations, including a total of 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago and the European Hematology Association (EHA) Congress taking place June 12-15 in Milan. These presentations include notable new data supporting the clinical actionability of clonoSEQ in both multiple myeloma (MM) and chronic lymphocytic leukemia (CLL).

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL.

Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Zacks Investment Research

Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?

Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.

Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?

Zacks Investment Research

Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy?

Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy?

Zacks Investment Research

Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect?

The consensus price target hints at a 26.5% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect?

See News Rankings

Charts implemented using Lightweight Charts™